Literature DB >> 8673540

Effects of human immunodeficiency virus type 1 infection on programmed cell death in the presence or absence of Bcl-2.

I W Park1, E Kondo, L Bergeron, J Park, J Sodroski.   

Abstract

The effect of human immunodeficiency virus (HIV-1) infection on the programmed cell death of CD4+ lymphocytes was studied by using Jurkat cells stably expressing high levels of the Bcl-2 protein (Jurkat-Bcl2) or control cells (Jurkat-P). Both Jurkat-Bcl2 and Jurkat-P cells exhibited surface CD4 expression adequate to support HIV-1 infection. We observed no differences between HIV-1-infected Jurkat Bcl2 cells and control cells with respect to kinetics of virus replication, protein expression, and processing. Severe cytopathic effects, which were typical of acute HIV-1 infection and consisted of syncytium formation followed by single-cell lysis, were observed in both cell types. However, several lines of evidence, such as cell viability analysis by trypan blue dye exclusion, chromosomal DNA laddering, and morphologic analysis by acridine orange/ethidium bromide or Giemsa staining, indicated that HIV-1 did not induce a significant amount of programmed cell death in either cell type. These results suggest that apoptosis is at most a minor element in HIV-1-induced cytopathicity in Jurkat lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673540     DOI: 10.1097/00042560-199608010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  7 in total

1.  Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability.

Authors:  Jayme Salsman; Deniz Top; Julie Boutilier; Roy Duncan
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  A major human immunodeficiency virus type 1-initiated killing pathway distinct from apoptosis.

Authors:  V Kolesnitchenko; L King; A Riva; Y Tani; S J Korsmeyer; D I Cohen
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.

Authors:  Elena Priceputu; Isabelle Rodrigue; Pavel Chrobak; Johanne Poudrier; Tak W Mak; Zaher Hanna; Chunyan Hu; Denis G Kay; Paul Jolicoeur
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Cytopathic killing of peripheral blood CD4(+) T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env.

Authors:  Michael J Lenardo; Sara B Angleman; Viengngeun Bounkeua; Joseph Dimas; Melody G Duvall; Moses B Graubard; Felicita Hornung; Marianne C Selkirk; Christina K Speirs; Carol Trageser; Jan O Orenstein; Diane L Bolton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription.

Authors:  Yan Zhou; Lin Shen; Hung-Chih Yang; Robert F Siliciano
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

7.  Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines.

Authors:  F Aillet; H Masutani; C Elbim; H Raoul; L Chêne; M T Nugeyre; C Paya; F Barré-Sinoussi; M A Gougerot-Pocidalo; N Israël
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.